Haw Par Corporation Ltd
SGX:H02
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
SG |
Haw Par Corporation Ltd
SGX:H02
|
2.2B SGD | 34.5 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
768.4B USD | 209 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.2T DKK | 44.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.3B USD | 15.5 | ||
US |
Merck & Co Inc
NYSE:MRK
|
331.5B USD | 22.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
192.3B GBP | 25.2 | ||
CH |
Roche Holding AG
SIX:ROG
|
185.5B CHF | 11.5 | ||
CH |
Novartis AG
SIX:NOVN
|
181.3B CHF | 14.4 | ||
US |
Pfizer Inc
NYSE:PFE
|
163.1B USD | 19 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.